Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 15, Issue 1, Pages -Publisher
SPRINGER
DOI: 10.1007/s11910-014-0512-2
Keywords
Myoclonus treatment; Movement disorder; Cortical myoclonus; Subcortical-nonsegmental myoclonus; Cortical-subcortical myoclonus; Segmental myoclonus; Myoclonus-dystonia; Deep brain stimulation
Categories
Funding
- Movement Disorders Society
- Medtronic, Inc.
- US World Meds
- Ipsen
- National Institutes of Health
- National Parkinson Foundation
- Michael J. Fox Foundation
- Avid Radiopharmaceuticals
- Dystonia Medical Research Foundation
- Solvay Pharmaceuticals Inc.
- Weill Medical College of Cornell University
- Merz Pharmaceuticals
Ask authors/readers for more resources
Recent advances in medications and surgical therapy for neurological disorders may offer new therapeutic options for the treatment of myoclonus. Appropriate therapy for myoclonus depends on the etiology, and in some cases, myoclonus can improve when the provoking cause is eliminated. When the underlying cause for the movements is not immediately reversible, localization, disease pathophysiology, and etiology may each play a role in determining the most appropriate symptomatic treatment of disabling myoclonic jerks. While the use of many agents is still based on small, open-label case series and anecdotes, there is a growing body of evidence from head-to-head comparative trials in several types of myoclonus that may help guide therapy. New therapies for refractory myoclonus, including sodium oxybate and even deep brain stimulation, are also being explored with increasing enthusiasm.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available